AS1810722|cas:909561-15-5|西域试剂

AS1810722,98.56%

产品编号：Bellancom-134772| CAS NO：909561-15-5| 分子式：C₂₅H₂₅F₂N₇O| 分子量：477.51

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-134772	￥3000.00	杭州北京（现货）
Bellancom-134772	￥4800.00	杭州北京（现货）
Bellancom-134772	￥9500.00	杭州北京（现货）
Bellancom-134772	￥14500.00	杭州北京（现货）
Bellancom-134772	￥22500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

AS1810722

产品介绍

AS1810722 是口服有效的 STAT6 抑制剂，IC₅₀ 为 1.9 nM。AS1810722 显示出良好的 CYP3A4 抑制作用。AS1810722 是一种稠合双环嘧啶衍生物，具有用于过敏性疾病，例如哮喘和特应性疾病研究的潜力。

生物活性

AS1810722 is an orally active and potent STAT6 inhibitor with an IC₅₀ of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.

体外研究

AS1810722 (compound 24) inhibits production of IL-4 with an IC₅₀ of 2.4 nM, but shows no effect on production of IFN-γ.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

AS1810722 (compound 24; 0.03-0.3 mg/kg; orally; 30 min before, and 24h and 48 h after OVA exposure) suppress eosinophil infiltration in the lung in a dose-dependent manner in an antigen-induced mouse asthmatic model.
AS1810722 inhibits in vitro Th2 differentiation with an IC₅₀ of 2.4 nM without affecting type 1 helper T (Th1) cell differentiation and eosinophil infiltration in an antigen-induced mouse asthmatic model after oral administration.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Balb/c mice asthmatic model by intraperitoneal injection of ovalbumin (OVA)-containing aluminum hydroxide gel
Dosage:	0.03-0.3 mg/kg
Administration:	Orally; 30 min before, and 24 and 48 h after OVA exposure
Result:	Suppressed eosinophil infiltration in the lung in a dose-dependent manner.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Balb/c mice asthmatic model by intraperitoneal injection of ovalbumin (OVA)-containing aluminum hydroxide gel
Dosage:	0.03-0.3 mg/kg
Administration:	Orally; 30 min before, and 24 and 48 h after OVA exposure
Result:	Suppressed eosinophil infiltration in the lung in a dose-dependent manner.

性状

Solid

溶解性数据

In Vitro:

DMSO : 62.5 mg/mL (130.89 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0942 mL	10.4710 mL	20.9420 mL
5 mM	0.4188 mL	2.0942 mL	4.1884 mL
10 mM	0.2094 mL	1.0471 mL	2.0942 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (4.36 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (4.36 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明